阿帕替尼联合放疗在非小细胞肺癌患者治疗中的应用前景研究

Application of apatinib combined with radiotherapy in the treatment of patients with non-small cell lung cancer

目的研究阿帕替尼联合放疗在非小细胞肺癌患者治疗中的应用前景。方法30例Ⅲ~Ⅳ期非小细胞肺癌患者,按照随机数字表法分为研究组和对照组,各15例。研究组患者给予阿帕替尼联合调强适形放疗,对照组患者给予调强适形放疗。对比两组治疗前后各项血清指标水平、生活质量评分、不良反应发生率。结果治疗后,研究组血清癌胚抗原、细胞角质蛋白19片段抗原21-1、血管内皮生长因子、基质金属蛋白酶-9水平分别为(14.14±2.28)、(4.39±0.65)、(282.46±32.35)、(988.47±105.38)ng/ml,均低于对照组的(18.47±2.16)、(5.96±0.71)、(487.42±51.38)、(1433.82±172.96)ng/ml,差异有统计学意义(P<0.05)。研究组躯体功能、心理健康、物质生活、社会能力、整体健康评分分别为(84.96±0.15)、(74.65±0.26)、(74.43±0.21)、(56.37±0.33)、(54.46±0.20)分,均高于对照组的(63.16±2.25)、(73.15±0.29)、(73.21±0.12)、(53.56±0.31)、(53.16±0.15)分,差异有统计学意义(P<0.05)。研究组不良反应发生率为20.00%,低于对照组的60.00%,差异有统计学意义(P<0.05)。结论阿帕替尼联合放疗治疗非小细胞肺癌能够有效的改善患者的各项临床指标,并且患者的不良反应发生率得到有效的控制,进而提高了患者的生活质量,值得临床推广。

Objective To study the application prospect of apatinib combined with radiotherapy in the treatment of patients with non-small cell lung cancer.Methods A total of 30 patients with stageⅢ-Ⅳnon-small cell lung cancer were divided into research group and control group according to the random numerical table,with 15 cases in each group.Patients in the research group received apatinib combined with intensity-modulated conformal radiotherapy,and patients in the control group received intensity-modulated conformal radiotherapy.The serum index levels and quality of life scores before and after treatment,and incidence of adverse reactions were compared between the two groups.Results After treatment,the serum carcinoembryonic antigen,cytokeratin 19 fragment antigen 21-1,vascular endothelial growth factor,and matrix metalloproteinase-9 levels in the research group were(14.14±2.28),(4.39±0.65),(282.46±32.35),and(988.47±105.38)ng/ml,respectively,which were lower than(18.47±2.16),(5.96±0.71),(487.42±51.38),and(1433.82±172.96)ng/ml in the control group,and the differences were statistically significant(P<0.05).The scores of somatic function,mental health,physical life,social competence,and overall health in the research group were(84.96±0.15),(74.65±0.26),(74.43±0.21),(56.37±0.33),and(54.46±0.20)points,respectively,which were higher than(63.16±2.25),(73.15±0.29),(73.21±0.12),(53.56±0.31),and(53.16±0.15)points in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the research group was 20.00%,which was lower than 60.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Apatinib combined with radiotherapy can effectively improve the clinical indicators of patients with non-small cell lung cancer,and the incidence of adverse reactions can be effectively controlled,thus improving the quality of life of patients,which is worthy of clinical promotion.